Medicine of post-traumatic stress disorder

Details Medicine of post-traumatic stress disorder Medicine of post-traumatic stress disorder

A - Human Necessities

61

K

A61K 31/5575 (2006.01) A61P 25/00 (2006.01)

Patent

CA 2440710

The treatment and/or prophylactic drugs of post-traumatic stress disorder (PTSD) containing compounds(EP, agonists), which activate EP, receptor that is subtype of prostaglandin E2 receptor, as an active ingredient. EP, agonists such as (13E)-(11 .alpha. , 15S, 17S)-2, 5-ethano-6, 9-dioxo-11, 15-dihydro-17, 20-dimethylprosta-13-enoic acid, PGE1, or PGE2, etc. are useful for the treatment of post-traumatic stress disorder (PTSD).

La présente invention concerne des agents de traitement et/ou de prévention de trouble du stress post-traumatique (ESPT) qui contiennent comme principe actif des composés agonistes du récepteur EP1 (c'est-à-dire, des agonistes EP1) qui est un sous-type du récepteur E2 de prostaglandine. Des agonistes EP1 tels que (13E)-(11 alpha , 15S, 17S) 2,5-éthano-6,9-dioxo-11,15-dihydroxy-17,20-diméthylprosta-13-acide énoïque, PGE1 et PGE2 sont utiles dans le traitement de l'ESPT.

Affiliated with

Also associated with

Rating

Medicine of post-traumatic stress disorder does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Medicine of post-traumatic stress disorder, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicine of post-traumatic stress disorder will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1513414